ExpreS2ion Biotech Holding AB (publ) filed its Annual on May 02, 2023 for the period ending Dec 31, 2022. In this report its auditor, Ernst & Young LLP, gave an unqualified opinion expressing doubt that the company can continue as a going concern.
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
1.31 SEK | -3.96% | -9.15% | -37.91% |
EPS Revisions
Annual profits - Rate of surprise
1st Jan change | Capi. | |
---|---|---|
-37.91% | 6.56M | |
-3.15% | 89.69B | |
+3.95% | 41.34B | |
-10.51% | 33.72B | |
+59.00% | 26.11B | |
-20.09% | 14.63B | |
-8.92% | 12.84B | |
-11.46% | 11.66B | |
-43.05% | 11.52B | |
+6.07% | 8.92B |
- Stock Market
- Equities
- EXPRS2 Stock
- News ExpreS2ion Biotech Holding AB
- ExpreS2ion Biotech Holding AB Auditor Raises 'Going Concern' Doubt